Release Notes  tranSMART Release Notes

Johnson & Johnson Clinical Trials in tranSMART Search

The following table shows the list of Johnson &  Johnson clinical trials that can be included in a tranSMART search result.

Trial

Title

Platform

C0168T37

A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients with Active Ulcerative Colitis.

Affymetrix Human Genome U133 Plus 2.0 array

C0168T44

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction Therapy Followed by Multiple Regimens of Maintenance Infliximab Therapy in Subjects with Plaque-type Psoriasis.

Affymetrix Human Genome U133 Plus 2.0 array

C0168T48

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Infliximab (REMICADE®) in Subjects with Chronic Sarcoidosis with Pulmonary Involvement.

RBM

C0379T02

A Phase I, Double-blind, Placebo-controlled Study Evaluating the Safety and Pharmacology of Single Subcutaneous Administrations of Human Monoclonal Antibody to IL-12 (CNTO 1275) in Subjects with Moderate to Severe Psoriasis Vulgaris.

DNA

C0379T03

A Phase I, Double-blind, Placebo-controlled Study Evaluating the Safety and Pharmacology of Single Subcutaneous Administrations of Human Monoclonal Antibody to IL-12 (CNTO 1275) in Subjects with Relapsing Forms of Multiple Sclerosis.

DNA

C0379T07

A Multicenter, Randomized, Phase 2a Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects With Moderately to Severely Active Crohn’s Disease.

Affymetrix Human Genome U133 Plus 2.0 array

C0524T03

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety Of CNTO 148 Administered Subcutaneously in Symptomatic Subjects With Severe Persistent Asthma.

Affymetrix Human Genome U133 Plus 2.0 array

C0743T10

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis.

RBM

C0743T12

A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis.

Affymetrix Human Genome U133 Plus 2.0 array

C0743X01

Detection of Mediators of Sarcoidosis Skin Lesions.

Affymetrix Human Genome U133 Plus 2.0 array, RBM